ArticleBMC microbiology2026
Multi-omics profiling of gut microbiota and host transcriptome identifies diagnostic signatures and mechanistic links in moyamoya disease.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundMoyamoya disease (MMD) features progressive intracranial artery stenosis and collateralization. Growing evidence implicates a dysregulated gut–brain axis in cerebrovascular pathology. We aimed to identify MMD-associated gut microbes and delineate the molecular mechanisms linking intestinal signals to vascular inflammation in MMD.
resultsWe profiled fecal microbiota using full-length 16S rRNA sequencing from 24 MMD patients and 20 matched controls, prioritizing taxa with LEfSe, LASSO, and random forest algorithms. A species-level diagnostic model showed robust discrimination in our cohort (ROC AUC = 0.9146), and DCA supported its clinical utility. To connect gut signals to host vascular responses, we integrated peripheral and vascular transcriptomes from GEO and a cross-disease cerebrovascular cohort. Differential expression, WGCNA, and LASSO analyses identified key MMD genes and their immune modules. We then intersected these with microbiome-derived, gut-related genes to nominate candidate mediators of gut–immune–vessel crosstalk. This multi-omics pipeline identified Fusobacterium nucleatum, Lachnoanaerobaculum cf. saburreum C27KA, and NK4A214_group as MMD-specific microbial markers. Crucially, these markers were associated with immune infiltration signatures and inflammatory pathway activation in diseased vessels. Further integration pinpointed QRFPR and HCAR2 as key mediators of gut-derived cerebrovascular inflammation, suggesting a potential microbiota–immune–vascular pathway along the gut–brain axis.
conclusionWe characterized an MMD-associated microbiota profile and proposed QRFPR and HCAR2 as candidate genes linking intestinal microbes to vascular immune activation. By mapping the gut–brain axis from microbial taxa to host receptors and vessel-wall transcriptional programs, this study uncovers potential disease mechanisms and highlights new avenues for microbiome-informed biomarkers and therapeutic targeting in MMD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.